Effect of Tocilizumab and Remdesivir on the Outcome of Patients with Covid 19 Pneumonia Admitted to Alabbasia Chest Hospital ICU

Abstract Background Coronavirus is one of the major pathogens that primarily targets the human respiratory system. Previous coronaviruses outbreaks of (CoVs) include the severe acute respiratory syndrome (SARS)-CoV and the Middle East respiratory syndrome (MERS)-CoV which have been considered as great public health threat. Aim of the Work This study aimed to find Effect of Tocilizumab and Remdesivir on the outcome of Patients with Covid 19 Pneumonia Admitted to Alabbasia Chest Hospital ICU. Patients and Methods This retrospective observational study was conducted on 90 cases of COVID 19 patients admitted to Respiratory Intensive Care Unit (RICU) in Abbassia Chest Hospital during the period between January 2021 to June 2021 and all the cases were subjected to full history taking, laboratory investigations and radiological assessment with chest x-ray and computed tomography. Results This current study showed that there was no statistically difference in the need of mechanical ventilation beween the patients who received Tocilizumab, the patients who received Remdisivir and the patients who received standard treatment. This study found that there was no statistically difference in the number of days on mechanical ventilation when it happened beween the patients who received Tocilizumab, the patients who received Remdisivir and the patients who received standard treatment. This current work showed that there was no statistically difference in the total length of staying at ICU beween the patients who received Tocilizumab, the patients who received Remdisivir and the patients who received standard treatment. This study revealed that there was no statistically difference in the final outcome beween the patients who received Tocilizumab, the patients who received Remdisivir and the patients who received standard treatment. This work showed that there was no statistically difference in the cause of death when happened beween the patients who received Tocilizumab, the patients who received Remdisivir and the patients who received standard treatment. These results could be attributed to the small sample size included in the current study which could affect the statistical significance level. Conclusion From this study we concluded that there was no statistically significant difference in the need of mechanical ventilation, number of days on mechanical ventilation, total length of staying at ICU, final outcome, and cause of death when it happened between the patients who received Tocilizumab, patients who received Remdisivir and the patient who received standard treatment.